Page 122 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

120
Chapter 6
20. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population. Neurology 2008;71:559–566.
21. Pijpers JA, Louter MA, De Bruin ME, et al. Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure? Cephalalgia 2016;36(2):122–130.
22. Bottiroli S, Allena M, Sances G, et al. Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six- month follow-up of the COMOESTAS Project. Cephalalgia 2019;39(1):135–147.Available from: http://journals.sagepub.com/doi/10.1177/0333102418783317
23. Kristoffersen ES, Straand J, Benth J, et al. Predictors of successful primary care detoxification treatment for medication-overuse headache. Acta Neurol. Scand. 2017;136(5):486–494.
24. Bottiroli S, Viana M, Sances G, et al. Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. Cephalalgia 2016;36(14):1356– 1365.
25. Sacco S, Bendtsen L, Ashina M, et al. Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain 2019;20(1):58.Available from: https:// thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-019-0972-5
26. Charles JA, Rapoport AM. The American Headache Society’s Position Statement on Integrating New Migraine Treatments into Clinical Practice – Comments. Headache J. Head Face Pain 2019;59(4):629–629.Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/head.13496
27. Tepper SJ, Diener H-C, Ashina M, et al. Erenumab in chronic migraine with medication overuse. Neurology 2019;92(20):e2309–e2320.Available from: http://www.neurology.org/lookup/ doi/10.1212/WNL.0000000000007497
28. Ray JC, Kapoor M, Stark RJ, et al. Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. J. Neurol. Neurosurg. Psychiatry 2021;
29. Hargreaves R, Olesen J. Calcitonin Gene-Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class. Headache 2019;1–20.
30. Green AL, Gu P, De Felice M, et al. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 2013;34(8):594–604.Available from: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=4103974&tool=pmcentrez&rendertype=abstract
31. Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine. Pain 2017;158(4):543–559.Available from: http:// insights.ovid.com/crossref?an=00006396-201704000-00003
32. Burstein R, Collins B, Jakubowski M. Defeating Migraine Pain with Triptans: A Race against the Development of Cutaneous Allodynia. Ann. Neurol. 2004;55(1):19–26.
33. Jakubowski M. 2005 Harold G . Wolff Award Winner Terminating Migraine With Allodynia and Ongoing Central Sensitization Using Parenteral Administration of COX1 / COX2 Inhibitors. herold G 2005;850–861.
34. Akerman S, Karsan N, Bose P, et al. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain 2019;142(1):103–119.
35. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post- treatment: Results from the rizatriptan TAME studies. Cephalalgia 2007;27(9):1055–1060.
36. De Icco R, Tassorelli C. Dissecting out migraine complexity through comprehensive analysis of allodynia. Brain 2019;142(1):5–8.Available from: https://academic.oup.com/brain/ article/142/1/5/5263722
37. Li L, Rutlin M, Abraira VE, et al. The functional organization of cutaneous low-threshold mechanosensory neurons. Cell 2011;147(7):1615–1627.
38. Schwedt TJ, Zuniga L, Chong CD. Low heat pain thresholds in migraineurs between attacks. Cephalalgia 2015;35(7):593–599.Available from: http://www.ncbi.nlm.nih.gov/ pubmed/25246520%5Cnhttp://cep.sagepub.com/cgi/doi/10.1177/0333102414550417
39. Sorge RE, Mapplebeck JCS, Rosen S, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat. Neurosci. 2015;18(8):1081–1083.Available from: http://www.nature.com/doifinder/10.1038/nn.4053